# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Steven Mah maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $65.
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing acti...
Guggenheim analyst Subbu Nambi initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Ta...
No limit to number of fragments included in the poolsOptimized chemistry enables direct synthesis of up to 500 bp double strand...